High­T­ide Ther­a­peu­tics rides NASH R&D wave with a $107M raise

High­T­ide Ther­a­peu­tics has raised a $107 mil­lion Se­ries C round to fund mid-stage stud­ies in meta­bol­ic and di­ges­tive dis­eases, with the goal of fil­ing for ap­proval in Chi­na with­in two to three years.

High­T­ide, which has roots in Shen­zhen, Chi­na, and Mary­land, dis­closed the round Thurs­day morn­ing in ad­vance of the JP­Mor­gan health­care meet­ing. CEO and founder Lip­ing Liu told End­points News the fi­nanc­ing would like­ly bankroll the com­pa­ny in­to the 2024 to 2025 time­frame.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER